In this study we investigated the function of the non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) and its correlation with ITGB1 and ITGB4 integrins in driving ovarian cancer (OvCa) aggressiveness. We also evaluated whether NCK2 may influence prognosis in OvCa patients.
Nanofluidic technology was used to analyze expression of NCK2 in 332 OvCa patients. To evaluate mRNA expression of NCK2, integrins and VEGFA in OvCa cell lines, qRT-PCR was performed. Stable NCK2 overexpression was obtained in OVCAR3. qRT-PCR and Western blot were performed to evaluate expression changes of VEGFA, vimentin, ITGB1, ITGB4, MMP2 and MMP9 under normoxia and hypoxia conditions. Coimmunoprecipitation (Co-IP) was performed in the A2780 cell line to study the interaction between NCK2 and proteins of interest. To investigate whether NCK2 can influence anchorage-independent growth, a soft agar assay was completed. Transwell invasion assay was performed on stable-transfected OVCAR-3 cell lines.
Nanofluidic data showed NCK2 can play an important role as a factor promoting tumor aggressiveness and survival in OvCa. This role was also linked to the behaviors of ITGB1 and ITGB4. Moreover, in cells overexpressing NCK2, the expression of vimentin, MMP2, MMP9, VEGFA and ITGB1, but not of ITGB4 was induced by hypoxia. Co-IP showed that NCK2 can directly bind ITGB1, but not VEGFA. NCK2 may be involved in mediating cell-extracellular matrix interactions in OvCa cells by influencing tumor aggressiveness.
This study provides evidence of a possible role of NCK2 as biomarker of OvCa progression.
Post author correction
Article Type: ORIGINAL RESEARCH ARTICLE
Article Subject: Biomarker discovery
AuthorsMara Fanelli, Alessia Camperchioli, Lella Petrella, Marco Petrillo, Cinzia Baranello, Pina Baccaro, Carmela Paolillo, Ettore Capoluongo, Giovanni Scambia
- • Accepted on 19/04/2017
- • Available online on 05/12/2017
This article is available as full text PDF.
- Fanelli, Mara [PubMed] [Google Scholar] 1
- Camperchioli, Alessia [PubMed] [Google Scholar] 2
- Petrella, Lella [PubMed] [Google Scholar] 1
- Petrillo, Marco [PubMed] [Google Scholar] 3
- Baranello, Cinzia [PubMed] [Google Scholar] 1, 4
- Baccaro, Pina [PubMed] [Google Scholar] 1
- Paolillo, Carmela [PubMed] [Google Scholar] 5
- Capoluongo, Ettore [PubMed] [Google Scholar] 1, 5, * Corresponding Author (firstname.lastname@example.org;)
- Scambia, Giovanni [PubMed] [Google Scholar] 1, 3
Laboratory of Molecular Oncology, Jean Paul 2nd Research Foundation, Campobasso - Italy
Research laboratory, Molipharma s.r.l, Campobasso - Italy
Department of Obstetrics and Gynecology, Catholic University and Foundation Gemelli Hospital, Rome - Italy
Danbury Hospital Research Institute, Danbury, Connecticut - USA
Laboratory of Clinical Molecular and Personalized Diagnostics, Institute of Biochemistry and Clinical Biochemistry, Catholic University and Foundation Gemelli Hospital, Rome - Italy
Mara Fanelli and Alessia Camperchioli contributed equally to this work.